Harold Glenn San Agustin
Infectious Disease · Los Angeles, CANPI 1215272067
Payments from drug & device makers
Across 276 payments — averaging $298.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$52K
- Viiv Healthcare Company$29K
- AbbVie$206
- Madrigal Pharmaceuticals$150
- Janssen Products, LP$149
- Dynavax Technologies Corporation$146
- plus $567 from 10 others
What the payments were for
- Consulting fees$13,22016%
- Speaking & faculty fees$53,93666%
- Travel & lodging$7,2169%
- Food & beverage$7,7359%
- Education$1490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 125 | $52,199 |
| Viiv Healthcare Company | 113 | $28,840 |
| AbbVie | 13 | $206 |
| Madrigal Pharmaceuticals | 1 | $150 |
| Janssen Products, LP | 2 | $149 |
| Dynavax Technologies Corporation | 3 | $146 |
| Johnson & Johnson | 6 | $131 |
| Shionogi Inc | 1 | $125 |
| Theratechnologies Inc. | 3 | $81 |
| Merck | 2 | $60 |
| GSK | 2 | $59 |
| Napo Pharmaceuticals Inc | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$82,256 in reported general payments places this provider in the 85th percentile of 856 infectious disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 93 | $377,566 |
| CabenuvaCabotegravir/Rilpivirine | 13 | $86,643 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 13 | $44,508 |
| OzempicSemaglutide | 25 | $28,372 |
| TivicayDolutegravir Sodium | 13 | $27,730 |
| EntrestoSacubitril/Valsartan | 13 | $8,745 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 11 | $429 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $393 |
| Doxycycline Hyclate | 20 | $288 |
| Fluticasone Propionate | 17 | $233 |
| Atorvastatin Calcium | 48 | $207 |
| Tamsulosin Hcl | 19 | $171 |
| Gabapentin | 11 | $120 |
| Metformin Hcl | 18 | $113 |
| Carvedilol | 17 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $52,199 | $377,56693 claims |
| Viiv Healthcare CompanyCabenuva, Tivicay | $28,840 | $114,37326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 856 infectious disease providers in California.
Other infectious disease in Los Angeles
- Peter RuaneLos Angeles$24.6M
- Raphael LandovitzLos Angeles$21.4M
- Jay GladsteinLos Angeles$4M
- Jesse ClarkLos Angeles$2M
- Jeffrey KlausnerLos Angeles$1.2M
- Otto YangLos Angeles$1.1M
- Michael DubeLos Angeles$742K
- Drew WinstonLos Angeles$697K
- Philip RobinsonNewport Beach$4.9M
- Shawn HasslerSan Francisco$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.